Otros idiomas Elutia Inc.

Acciones

ELUT

US05479K1060

Mercado cerrado - Nasdaq Otros sitios de cotización 22:30:00 01/05/2024			Varia. Cinco días.	Varia. 1 de enero.
2,85 ^USD	+2,89 %		-1,38 %	+31,94 %

07/03	Transcript : Elutia Inc., Q4 2023 Earnings Call, Mar 07, 2024
07/03	Elutia Inc. informa de los resultados del cuarto trimestre finalizado el 31 de diciembre de 2023	CI

Otros idiomas

Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!

Inscripción 100% Gratuita

Elutia to Present at the Planet MicroCap Showcase: VEGAS 2024 on Wednesday, May 1	24/04
Elutia Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	07/03
Elutia Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	07/03
Earnings Flash (ELUT) ELUTIA Posts Q4 Revenue $5.9M, vs. Street Est of $6.6M	07/03
Elutia Reports Fourth Quarter and Full Year 2023 Financial Results: Anticipates CanGarooRM® Clearance Decision in First Half of 2024	07/03
Elutia to Report Fourth Quarter and Full Year 2023 Financial Results on Thursday, March 7, 2024	22/02
Elutia's CanGarooRM: Pioneering Drug-Eluting Biologic for Secure Medical Implants	20/02
Elutia Regains Compliance with Nasdaq Listing Requirements	10/01
Elutia Submits CanGarooRM® Antibiotic-Eluting Biomatrix for FDA Clearance	18/12
Elutia Submits CanGaroo Antibiotic-Eluting Biomatrix for FDA Clearance	18/12
Elutia : The Wall Street Transcript	05/12
Elutia Inc. Amendments to Credit Agreement with SWK Funding LLC	15/11
Elutia Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	13/11
Earnings Flash (ELUT) ELUTIA Reports Q3 Revenue $6.1M, vs. Street Est of $7.3M	13/11
Elutia Reports 26% Year-Over-Year Sales Growth of Proprietary Products and Strengthened Balance Sheet in Third Quarter 2023 Financial Results	13/11
Elutia Completes Divestiture of Orthobiologics Business Unit for Cash Proceeds of Up to $35 Million	09/11
Berkeley Biologics, LLC completed the acquisition of Orthobiologics business unit of Elutia Inc. for $34.6 million.	08/11
Elutia to Report Third Quarter 2023 Financial Results on Monday, November 13, 2023	06/11
Top Premarket Gainers	06/10/23
Elutia Inc. announced that it has received $10.5 million in funding from HighCape Partners Management, L.P., Nantahala Capital Management, LLC	03/10/23

No hay resultados para esta búsqueda

Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Otros idiomas Elutia Inc.

Acciones

ELUT

US05479K1060

Otros idiomas

Filtros